Angios Biotech

Angios Biotech is a private, pre-clinical stage biotech firm developing innovative vascular disease treatments and research tools. Its core asset is a proprietary, patented platform that generates human blood vessel organoids from iPSCs, aiming to overcome the limitations of animal models. The company is advancing antibody therapeutics for diabetic complications in partnership with Abcellera, developing vascular transplants, and commercializing its organoid platform for drug screening. With a lean, science-driven team based in Austria and operations in the US and Canada, Angios is positioning itself at the intersection of vascular biology, regenerative medicine, and animal-free testing.

Patented platform for generating 3D human Blood Vessel Organoids (BVOs) from induced pluripotent stem cells (iPSCs) for disease modeling, drug screening, and regenerative medicine.

Angios competes in the vascular disease space with large pharma and biotechs, and in the organoid/drug screening tool space with companies like Emulate, Mimetas, and Stemcell Technologies. Its differentiation lies in its specific, patented focus on iPSC-derived 3D human vasculature, a critical and complex tissue niche.